Abstract 2640
Background
Desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft tissue tumour, which by local growth can significantly impact health related quality of life (HRQL). We aimed to identify the most important HRQL-issues of DTF patients.
Methods
DTF patients and health care professionals (HCPs) from the Netherlands and the United Kingdom individually ranked 124 issues according to their relevance. Patients also completed the European Organisation for Research and Treatment of Cancer QLQ-C30 core questionnaire (EORTC QLQ-C30). Outcomes of both groups were used to identify the most important HRQL-issues.
Results
The most highly ranked issues by patients (n = 29) were issues concerning ‘tumour growth’, ‘feeling that there is something in the body that does not belong there’, and ‘fear of tumour growth into adjacent tissues or organs’ with mean scores of 3.0, 2.9 and 2.8 respectively out of a total of 4 points. British patients scored higher on most issues compared to Dutch patients. Similarly, all HCPs (n = 31) gave higher scores on most issues compared to patients (total mean score of 2.3 versus a total mean of 1.9 for patients). The EORTC QLQ-C30 sum of scores was relatively high with a mean score of 77 points out of 100.
Conclusions
Patients affected by DTF experience psychological issues regarding the unpredictable tumour growth behaviour. Validation in a large international cohort is needed to devise a HRQL-questionnaire specific to DTF patients to fully address their needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Stichting Coolsingel Rotterdam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract